Literature DB >> 19247660

Early onset neutropenia after mycophenolate mofetil in systemic sclerosis.

Giovanna Cuomo, Giuseppina Abignano, Gabriele Valentini.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19247660     DOI： 10.1007/s00296-009-0879-6

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN： 0172-8172            Impact factor:   2.631


× No keyword cloud information.
  10 in total

1.  Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis.

Authors:  Ellen M Ginzler; Mary Anne Dooley; Cynthia Aranow; Mimi Y Kim; Jill Buyon; Joan T Merrill; Michelle Petri; Gary S Gilkeson; Daniel J Wallace; Michael H Weisman; Gerald B Appel
Journal:  N Engl J Med       Date:  2005-11-24       Impact factor: 91.245

2.  Mycophenolate mofetil in diffuse cutaneous systemic sclerosis--a retrospective analysis.

Authors:  S I Nihtyanova; G M Brough; C M Black; C P Denton
Journal:  Rheumatology (Oxford)       Date:  2006-08-09       Impact factor: 7.580

Review 3.  Review of major clinical trials with mycophenolate mofetil in cardiac transplantation.

Authors:  Jon A Kobashigawa; Bruno M Meiser
Journal:  Transplantation       Date:  2005-10-15       Impact factor: 4.939

Review 4.  Review of major clinical trials with mycophenolate mofetil in renal transplantation.

Authors:  Gaetano Ciancio; Joshua Miller; Thomas A Gonwa
Journal:  Transplantation       Date:  2005-10-15       Impact factor: 4.939

5.  Mycophenolate mofetil-induced neutropenia in liver transplantation.

Authors:  F Nogueras; M D Espinosa; A Mansilla; J T Torres; M A Cabrera; R Martín-Vivaldi
Journal:  Transplant Proc       Date:  2005-04       Impact factor: 1.066

6.  Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group.

Authors:  T M Chan; F K Li; C S Tang; R W Wong; G X Fang; Y L Ji; C S Lau; A K Wong; M K Tong; K W Chan; K N Lai
Journal:  N Engl J Med       Date:  2000-10-19       Impact factor: 91.245

7.  Mycophenolate mofetil prevents transplant arteriosclerosis by direct inhibition of vascular smooth muscle cell proliferation.

Authors:  Hisashi Shimizu; Masafumi Takahashi; Shin-Ichi Takeda; Seiichiro Inoue; Jun Fujishiro; Yoji Hakamata; Takashi Kaneko; Takashi Murakami; Koichi Takeuchi; Izumi Takeyoshi; Yasuo Morishita; Eiji Kobayashi
Journal:  Transplantation       Date:  2004-06-15       Impact factor: 4.939

8.  Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease.

Authors:  S N C Liossis; A Bounas; A P Andonopoulos
Journal:  Rheumatology (Oxford)       Date:  2006-02-20       Impact factor: 7.580

9.  Mycophenolic acid inhibits activation of inducible nitric oxide synthase in rodent fibroblasts.

Authors:  Dj Miljkovic; I Cvetkovic; S Stosic-Grujicic; V Trajkovic
Journal:  Clin Exp Immunol       Date:  2003-05       Impact factor: 4.330

10.  A pilot study of mycophenolate mofetil combined to intravenous methylprednisolone pulses and oral low-dose glucocorticoids in severe early systemic sclerosis.

Authors:  M Vanthuyne; D Blockmans; R Westhovens; F Roufosse; E Cogan; E Coche; A Nzeusseu Toukap; G Depresseux; F A Houssiau
Journal:  Clin Exp Rheumatol       Date:  2007 Mar-Apr       Impact factor: 4.473
  10 in total
  1 in total

Review 1.  Safety and effectiveness of mycophenolate in systemic sclerosis. A systematic review.

Authors:  Mohammed A Omair; Abdulaziz Alahmadi; Sindhu R Johnson
Journal:  PLoS One       Date:  2015-05-01       Impact factor: 3.240
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.